Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Emerging PD-L1 Inhibitors for HNSCC

December 22nd 2016

Ongoing Research of Immunotherapy in HNSCC

December 22nd 2016

Patient Selection for Nivolumab in HNSCC

December 22nd 2016

Nivolumab-Related Efficacy and Toxicity in HNSCC Patients

December 22nd 2016

Nivolumab: A New Standard-of-Care

December 22nd 2016

Immunotherapy for Recurrent HNSCC

December 22nd 2016

The Approval of Pembrolizumab for Recurrent HNSCC

December 22nd 2016

Immunotherapy for Virally Induced vs High-Mutation Burden HNSCC

December 22nd 2016

Mechanisms of Immunotherapy in HNSCC

December 22nd 2016

Historic Perspective on Recurrent HNSCC

December 22nd 2016

Historic Perspective on Systemic Therapy for Advanced HNSCC

December 22nd 2016

Multimodality Treatment for HNSCC

December 22nd 2016

Risk Stratification for HNSCC

December 22nd 2016

Biology of Head and Neck Squamous Cell Cancer (HNSCC)

December 22nd 2016

Dr. Dadu on Treatment Approaches in Medullary Thyroid Cancer

December 22nd 2016

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches in medullary thyroid cancer.

Concomitant Chemo Regimens Most Effective for Locally Advanced Nasopharyngeal Carcinoma

December 22nd 2016

The addition of chemotherapy, either adjuvant or induction, to concomitant chemoradiotherapy achieved a significantly high survival benefit for patients with locally advanced nasopharyngeal carcinoma.

In Head and Neck Cancer, a Stepped Approach to Psychosocial Care Is Cost-Effective

December 20th 2016

Patients diagnosed with head and neck or lung cancer are especially prone to feelings of distress, especially depression, and researchers in the Netherlands have found that using a gradual or “stepped” approach to providing psychosocial support not only improves their quality of life but is also cost-effective.

Dr. de Souza on Next Steps for Immunotherapy in Head and Neck Cancer

December 20th 2016

Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.

Dr. Burtness on the Use of Immunotherapy After Chemoradiation in Head and Neck Cancer

December 15th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the use of immunotherapy in patients with head and neck cancer who have residual disease following treatment with chemotherapy and radiation.

Dr. Koyfman on Risk Categories in the Reirradiation Setting of Recurrent Head and Neck Cancer

December 15th 2016

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses risk categories that stratified patients in a study evaluating intensity-modulated radiation therapy and stereotactic body radiation therapy to determine outcomes in the reirradiation setting for recurrent head and neck cancer.